Longitudinal PET Imaging Reveals the Biological Fate, Pharmacokinetics, and Clearance of Zirconium-89-Labeled MXene Nanosheets In Vivo.
- 1Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.
- 2University of Science and Technology (UST), 217, Gajeong-ro, Yuseong-gu, Daejeon 34113, Republic of Korea.
- 3Department of Chemistry, Pakistan Institute of Engineering and Applied Sciences (PIEAS), P.O. Nilore, Islamabad 45650, Pakistan.
Abstract
Two-dimensional MXene (Ti₃C₂Tx) nanosheets have emerged as versatile platforms for drug delivery, photothermal and photodynamic therapy, combined chemo-photothermal treatment, and multimodal imaging including MRI and CT, as well as theranostic applications. However, their clinical translation is limited by an incomplete understanding of their long-term in vivo fate, pharmacokinetics, and biological interactions following systemic administration. Here, we developed a stable zirconium-89-labeled MXene platform via DFO-mediated chelation to enable quantitative, noninvasive, and longitudinal positron emission tomography (PET) imaging over 21 days. Comprehensive physicochemical characterization confirmed successful synthesis, surface functionalization, and radiolabeling of MXene nanosheets, yielding a radiochemical purity of 99.39 ± 0.66% and serum stability exceeding 97.3±1.9% over 7 days. PET/CT imaging and biodistribution studies revealed an initial pulmonary accumulation phase (30.43 ± 5.39 %ID/g), followed by progressive sequestration within the reticuloendothelial system, predominantly in the liver (maximum 30.16 ± 5.42 %ID/g on day 7) and spleen (9.31±3.17 %ID/g on day 7). Quantitative biodistribution analysis further demonstrated prolonged organ retention with gradual elimination through both renal and hepatobiliary pathways, as confirmed by excretion studies. Minimal skeletal uptake (<1.04±0.14 %ID/g throughout the study) indicated excellent in vivo radiolabel stability. Histopathological examination of major organs, together with in vitro cytotoxicity assays, revealed no significant adverse effects despite prolonged tissue retention. Collectively, these findings provide insight into the nano-bio interactions governing MXene biodistribution, organ accumulation, and clearance. More broadly, this study establishes a PET-based framework for evaluating the biological fate and safety of emerging two-dimensional nanomaterials and supports the rational development of MXene-based nanotheranostic platforms for biomedical applications.
Related
- Dynamic lactate clearance within the first 48 hours predicts pressure injury during ECMO support: a longitudinal cohort study.
- Rapid Clearance of microRNA-371a-3p: A Longitudinal Study of Serum Levels in Patients with Localized Testicular Germ Cell Tumors.
- Longitudinal Associations between the Built Environment, Biological Aging and Cognition
- Age-related biological dysregulation quantified using metabolomics is composed of distinct subsystems with synergistic associations to health outcomes: An analysis of the Canadian Longitudinal Study on Aging
- The Endoscopic Removal of a Gastric Bezoar Made of Sodium Zirconium Cyclosilicate Hydrate
BibTeX
@article{bibi2026longitudinal,
title = {{Longitudinal PET Imaging Reveals the Biological Fate, Pharmacokinetics, and Clearance of Zirconium-89-Labeled MXene Nanosheets In Vivo.}},
author = {Iqra Bibi and Sairan Eom and Sang Jin Han and Kyung Jun Kang and Jung Young Kim and Sajid Mushtaq and Ji-Ae Park},
journal = {Nanotheranostics},
year = {2026},
month = oct,
doi = {10.7150/ntno.138975},
url = {https://europepmc.org/article/MED/42910405},
note = {CC BY},
}
RIS
TY - JOUR
TI - Longitudinal PET Imaging Reveals the Biological Fate, Pharmacokinetics, and Clearance of Zirconium-89-Labeled MXene Nanosheets In Vivo.
AU - Iqra Bibi
AU - Sairan Eom
AU - Sang Jin Han
AU - Kyung Jun Kang
AU - Jung Young Kim
AU - Sajid Mushtaq
AU - Ji-Ae Park
PY - 2026
DA - 2026/10/09
JO - Nanotheranostics
DO - 10.7150/ntno.138975
UR - https://europepmc.org/article/MED/42910405
AB - Two-dimensional MXene (Ti₃C₂Tx) nanosheets have emerged as versatile platforms for drug delivery, photothermal and photodynamic therapy, combined chemo-photothermal treatment, and multimodal imaging including MRI and CT, as well as theranostic applications. However, their clinical translation is limited by an incomplete understanding of their long-term in vivo fate, pharmacokinetics, and biological interactions following systemic administration. Here, we developed a stable zirconium-89-labeled MXene platform via DFO-mediated chelation to enable quantitative, noninvasive, and longitudinal positron emission tomography (PET) imaging over 21 days. Comprehensive physicochemical characterization confirmed successful synthesis, surface functionalization, and radiolabeling of MXene nanosheets, yielding a radiochemical purity of 99.39 ± 0.66% and serum stability exceeding 97.3±1.9% over 7 days. PET/CT imaging and biodistribution studies revealed an initial pulmonary accumulation phase (30.43 ± 5.39 %ID/g), followed by progressive sequestration within the reticuloendothelial system, predominantly in the liver (maximum 30.16 ± 5.42 %ID/g on day 7) and spleen (9.31±3.17 %ID/g on day 7). Quantitative biodistribution analysis further demonstrated prolonged organ retention with gradual elimination through both renal and hepatobiliary pathways, as confirmed by excretion studies. Minimal skeletal uptake (<1.04±0.14 %ID/g throughout the study) indicated excellent in vivo radiolabel stability. Histopathological examination of major organs, together with in vitro cytotoxicity assays, revealed no significant adverse effects despite prolonged tissue retention. Collectively, these findings provide insight into the nano-bio interactions governing MXene biodistribution, organ accumulation, and clearance. More broadly, this study establishes a PET-based framework for evaluating the biological fate and safety of emerging two-dimensional nanomaterials and supports the rational development of MXene-based nanotheranostic platforms for biomedical applications.
SN - 2206-7418
ER -